Home >> Chemicals Listing >> hot product list by I  

Imidazo[4,5-d][1,3]diazepin-8-ol,3-(2-deoxy-b-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-,(8R)- (53910-25-1)

Identification
Name:Imidazo[4,5-d][1,3]diazepin-8-ol,3-(2-deoxy-b-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-,(8R)-
Synonyms:Imidazo[4,5-d][1,3]diazepin-8-ol,3-(2-deoxy-b-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-,(R)-;2'-DCF;2'-Deoxycoformycin;2'-Dexoycoformycin;CI 825;CL 67310465;Cl825;Co-V;Co-Vidarabine;Coforin;Deaminase inhibitor;Deoxycoformycin;NSC218321;NSC 247520;Nipent;PD-ADI;Pentostatin;Vira A deaminase inhibitor;
CAS:53910-25-1
Molecular Formula: C11H16N4O4
Molecular Weight: 268.26914
InChI: InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6?,7-,8?,9?/m1/s1
Molecular Structure: (C11H16N4O4) Imidazo[4,5-d][1,3]diazepin-8-ol,3-(2-deoxy-b-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-,(R)-;2'-...
Properties
Melting Point: 220-225ºC
Flash Point: 344.5 ºC
Boiling Point: 646 ºC at 760 mmHg
Density:1.81 g/cm3
Refractive index:1.793
Water Solubility:Soluble to 100 mM in Water and to 75 mM in DMSO
Solubility:Soluble to 100 mM in Water and to 75 mM in DMSO
Appearance:White crystals
Specification:

The IUPAC name of (8R)-3-[(2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol is (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol. With the CAS registry number 53910-25-1, it is also named as Pentostatin. The product's classification codes are Antineoplastic Agents; Drug / Therapeutic Agent; Enzyme Inhibitors; Human Data; Potentiator; Reproductive Effect, and the other registry numbers are 59979-24-7; 63677-95-2; 69196-00-5; 70865-77-9. Besides, this chemical is white crystals, which is soluble to 100 mM in water and to 75 mM in DMSO.

The other characteristics of this product can be summarized as: (1)ACD/LogP: -3.50; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): -4.16; (4)ACD/LogD (pH 7.4): -3.88; (5)ACD/BCF (pH 5.5): 1; (6)ACD/BCF (pH 7.4): 1; (7)ACD/KOC (pH 5.5): 1; (8)ACD/KOC (pH 7.4): 1; (9)H bond acceptors: 8; (10)H bond donors: 4; (11)Freely Rotating Bonds: 5; (12)Index of Refraction: 1.793; (13)Molar Refractivity: 62.65 cm3; (14)Molar Volume: 147.4 cm3; (15)Surface Tension: 82.3 dyne/cm; (16)Density: 1.81 g/cm3; (17)Flash Point: 344.5 °C; (18)Melting Point: 220 °C; (19)Enthalpy of Vaporization: 100.14 kJ/mol; (20)Boiling Point: 646 °C at 760 mmHg; (21)Vapour Pressure: 1.43E-17 mmHg at 25 °C.

Mass Production of (8R)-3-[(2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol: it can producing by dipping or submerged culturing of Streptomyces antibioticus. Frist, you can embed culture medium in water-soluble nutrient solution which has been sterilized. Then you can aerate and stir until the culture solution appear Pentostatin. After separation and purification, you can get this chemical.

Uses of (8R)-3-[(2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol: this chemical is classified as a purine analog, which is a type of antimetabolite. It also has been used to treat hairy cell leukemia. In addition, it is used in CLL patients who have relapsed. And it is used to treat steroid-refractory acute and chronic graft-versus-host disease.

People can use the following data to convert to the molecule structure.
(1)SMILES:n1c3c(n(c1)[C@@H]2O[C@@H]([C@@H](O)C2)CO)N\C=N/C[C@H]3O
(2)InChI:InChI=1/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1
(3)InChIKey:FPVKHBSQESCIEP-JQCXWYLXBA
(4)Std. InChI:InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1
(5)Std. InChIKey:FPVKHBSQESCIEP-JQCXWYLXSA-N

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LDLo intravenous 360mg/kg (360mg/kg) SENSE ORGANS AND SPECIAL SENSES: MIOSIS (PUPILLARY CONSTRICTION): EYE

GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS

GASTROINTESTINAL: NAUSEA OR VOMITING
Kiso to Rinsho. Clinical Report. Vol. 24, Pg. 7888, 1990.
mouse LD50 intravenous 122mg/kg (122mg/kg) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
National Technical Information Service. Vol. PB84-211424,
mouse LD50 oral 227mg/kg (227mg/kg) KIDNEY, URETER, AND BLADDER: HEMATURIA Kiso to Rinsho. Clinical Report. Vol. 24, Pg. 7888, 1990.
women LDLo unreported 390mg/kg/3D-I (390mg/kg) KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"

BLOOD: THROMBOCYTOPENIA

BLOOD: OTHER HEMOLYSIS WITH OR WITHOUT ANEMIA
Internal Medicine. Vol. 34, Pg. 593, 1995.

Biological Activity: Irreversible inhibitor of adenosine deaminase (K i = 2.5 pM). Anticancer agent.
Flash Point: 344.5 ºC
Color: White crystals from methanol/water
White to off-white solid
Usage:An adenosine deaminase inhibitor used as an anti-cancer therapeutic drug. Shown to be effective in the treatment of hairy cell leukemia as well as having use in the treatment of other types of cancer such as chronic lymphocytic leukemia.
Safety Data
 

Other Product